Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-A01590-45 | Other Identifier | RCB number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of the study is to show that the multidisciplinary review of drug prescriptions changes the adverse drug event (ADE) geriatric risk score (according to Trivalle and Ducimetière 2013) for patients living in the Nîmes University Hospital Residence for Dependent Elderly.
The secondary objectives of this study are to assess and compare the following criteria before and after multidisciplinary review of drug prescriptions for patients in the Nîmes University Hospital Residence for Dependent Elderly:
A. the number of patients with at least one potentially inappropriate drug prescribed
B. the number of hospitalizations
C. death rate
D. the number of falls per patient and the rate of fallers
E. qualitative criteria describing the drug review
F. associated care costs
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The study population | Other | See inclusion and exclusion criteria. Intervention: Before-after study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Before-after study | Other | The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase. The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score. The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence. During the second observational phase, the same data as in the first observational phase will be collected a second time. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Drug Events Geriatric Risk Score | according to Trivalle and Ducimetière 2013 | change from Baseline to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| The number of patients taking at least 1 potentially inappropriate drug according to Laroche criteria | Laroche et al 2007. | During the proactive phase. Day 0. |
| Number of hospitalizations in the public sector (higher level care) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Géraldine Leguelinel, Pharm-D | Centre Hospitalier Universitaire de Nīmes | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU de Nîmes - Centre de Gérontologie de Serre Cavalier | Nîmes | 30029 | France | |||
| CHRU de Nîmes - Hôpital Universitaire Carémeau |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| first observational phase (month -6 to day 0) |
| Number of hospitalizations in the public sector (higher level care) | second observational phase (day 0 to month 6) |
| Days of hospitalization in the public sector (higher level care) | first observational phase (month -6 to day 0) |
| Days of hospitalization in the public sector (higher level care) | second observational phase (day 0 to month 6) |
| Mortality | first observational phase (month -6 to day 0) |
| Mortality | second observational phase (day 0 to month 6) |
| The number of falls per patient | first observational phase (month -6 to day 0) |
| The number of falls per patient | second observational phase (day 0 to month 6) |
| The percentage of patients who fell | first observational phase (month -6 to day 0) |
| The percentage of patients who fell | second observational phase (day 0 to month 6) |
| The Anatomical Therapeutic Chemical classification for each revised drug | during the proactive phase (day 0) |
| The type of errors detected during drug review | Contra-indication, dosing, route, etc | during the proactive phase (day 0) |
| The type of modification suggested during drug review | discontinuation, addition, substitution... | during the proactive phase (day 0) |
| The acceptation rate for modifications suggested during drug review | during the proactive phase (day 0) |
| Associated care costs (€) | first observational phase (month -6 to day 0) |
| Associated care costs (€) | second observational phase (day 0 to month 6) |
| Nîmes |
| 30029 |
| France |
| ID | Term |
|---|---|
| D065187 | Controlled Before-After Studies |
| ID | Term |
|---|---|
| D016021 | Epidemiologic Studies |
| D016020 | Epidemiologic Study Characteristics |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
Not provided
Not provided